Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 49.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,872 shares of the medical research company’s stock after selling 2,804 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Bio-Rad Laboratories were worth $650,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Bio-Rad Laboratories by 9,953.4% during the 1st quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock worth $345,478,000 after acquiring an additional 1,715,872 shares during the period. Vanguard Group Inc. raised its holdings in shares of Bio-Rad Laboratories by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,673,274 shares of the medical research company’s stock worth $333,550,000 after acquiring an additional 58,774 shares during the period. TimesSquare Capital Management LLC raised its holdings in shares of Bio-Rad Laboratories by 17.2% during the 1st quarter. TimesSquare Capital Management LLC now owns 611,700 shares of the medical research company’s stock worth $121,936,000 after acquiring an additional 89,800 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Bio-Rad Laboratories by 1.7% during the 1st quarter. Alliancebernstein L.P. now owns 335,197 shares of the medical research company’s stock worth $66,818,000 after acquiring an additional 5,647 shares during the period. Finally, Fisher Asset Management LLC raised its holdings in shares of Bio-Rad Laboratories by 1.9% during the 2nd quarter. Fisher Asset Management LLC now owns 279,589 shares of the medical research company’s stock worth $63,274,000 after acquiring an additional 5,233 shares during the period. Institutional investors own 62.85% of the company’s stock.

BIO has been the topic of several analyst reports. BidaskClub lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price objective for the stock from $220.00 to $195.00 in a research report on Wednesday, June 28th. Zacks Investment Research downgraded Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price objective for the company. Finally, Jefferies Group LLC reissued a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $228.80.

Bio-Rad Laboratories, Inc. (BIO) opened at 224.33 on Friday. The firm has a 50-day moving average price of $221.37 and a 200 day moving average price of $216.87. Bio-Rad Laboratories, Inc. has a 52-week low of $154.89 and a 52-week high of $242.79. The firm has a market capitalization of $6.65 billion, a P/E ratio of 443.34 and a beta of 0.93.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Thompson Siegel & Walmsley LLC” was published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/markets/bio-rad-laboratories-inc-bio-holdings-trimmed-by-thompson-siegel-walmsley-llc/1600566.html.

In related news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.29% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.